Searching for the Best Drug Combination to Treat Melanoma Patients: From Lab to Bedside
December 2016 | Volume 15 | Issue 12 | Editorials | 1580 | Copyright © December 2016
María Sol Brassesco PhD,a Elvis Terci Valera MD PhD,b Julia Alejandra Pezuk PhD,c Karina Bezerra Salomão MSc,c Carlos Alberto Scrideli MD PhD,b and Luiz Gonzaga Tone MD PhDb
aDepartment of Biology, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto, University of São Paulo, Brazil. bDepartment of Pediatrics, Ribeirão Preto School of Medicine, University of São Paulo, Brazil cDepartment of Genetics, Ribeirão Preto School of Medicine, University of São Paulo, Brazil
these new drugs repertoire and systematically evaluated by clinical models.
The authors have no conflicts of interest to declare. This study was sponsored by CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil) Grant number 471952/2011-7.
- Ledford H. Melanoma drug wins US approval. Nature. 2011;471:561.
- Niezgoda A, Niezgoda P, Czajkowski R. Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int. 2015; 851387.
- de Oliveira JC, Brassesco MS, Pezuk JA, et al. In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells. J Drugs Dermatol. 2012;11(5):587-92.
- Haupenthal J, Bihrer V, Korkusuz H, et al. Reduced efficacy of the plk1 inhibitor bi 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels. Neoplasia. 2012;14:410-419.
- Wu CP, Hsiao SH, Sim HM, etal. Human ABCB1 (p-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of polo-like kinase 1. Biochem Pharmacol. 2013;86:904-913.
- Mross K, Dittrich C, Aulitzky WE, et al. A randomised phase II trial of the polo-like kinase inhibitor BI 2536 in chemo-naive patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the central european society anticancer drug research (CESAR) collaborative network. Br J Cancer. 2012;107:280-286.
- Fogh J, Orfeo T, Tiso J, et al. Twenty-three new human tumor lines established in nude mice. Exp Cell Biol. 1980;48:229-239.
- Brasseur F. Melanoma: Brussels melanoma Cells lines. In: Human cell culture Vol I Cancer cell lines Part 1 (Masters J, Palsson B eds) Kluber Academic Publishers, London UK, 2006:275-283.
- Brassesco MS, Pezuk JA, Morales AG, et al. In vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors. Cancer Biol Ther. 2013;14:648-657.
- Bogado RF, Pezuk JA, de Oliveira HF, et al. BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments. Anticancer Drugs. 2015;26:56-63.
- Gerster K, Shi W, Ng B, et al. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2010;77:253-260.
- Krause M, Kummer B, Deparade A, Eicheler W, P tzmann D, Yaromina A, et al. Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation. Radiother Oncol. 2013;108:422-428.
- Harris PS, Venkataraman S, Alimova I, et al. Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. BMC Cancer. 2012;12:80-93.
- Pezuk JA, Brassesco MS, Morales AG, et al. Inhibition of polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation. Cancer Biother Radiopharm. 2013;28:516-522.
- Lv P, Wang Y, Ma J, et al. Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair. Oncotarget. 2014;5:7512-7524.
- Rodel F, Keppner S, Capalbo G, et al. Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer. Am J Pathol. 2010;177:918-929.
- Lund-Andersen C, Patzke S, Nahse-Kumpf V, et al. PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule. Radiother Oncol. 2014;110:355-361.
- Ascierto PA, Marincola FM, Atkins MB. What’s new in melanoma? Combination! J Transl Med. 2015;13:213-217.
María Sol Brassesco PhD firstname.lastname@example.org